Pilar M. Samper Ots, José Zapatero Ortuño, Sara Pedraza Fernández, Esther Mayrata Canellas, Carmen González San Segundo, Maider Campo Vargas, Begoña Caballero, Mónica Ramos Albiac, Gonzalo Vázquez Masedo, Beatriz Álvarez, Silvia Rodríguez Villalba, Teresa Muñoz Miguelañez, Patricia Diezhandino García, Gemma Sancho, Laura Guzmán Gómez, Juana Tripero Oter, Mikel Rico Rico Oses,Carmen Ibañez Villoslada, Ana María Soler Soler Rodríguez, María Luisa Chust, Adriana Fondevilla Soler,Eva Maria Lozano Martín,Virginia Morillo Macias, Claudio Fuentes Sánchez, Laura Torrado Moya, Jesús Fernández López, Josep María Solé, Marcos Guijarro Verdú, Moisés Mira Flores, Amadeo Wals, José Expósito Hernández.
Radiother Oncol . 2021 Aug;161: 148 151. Published online 2021 Jun 10. doi: 10.1016/j.radonc.2021.06.001.
On December 31, 2019 a cluster of cases of pneumonia were first described in Wuhan, caused by a novel type of coronavirus called SARS CoV 2. This virus causes various clinical manifestations encompassed under the term COVID-19.
On March 11, 2020 the World Health Organization declared COVID-19 a global pandemic. In Spain, the most critical period was between February 15 and May 15, 2020. During this time, various different case definitions were provided. Initial data showed that patients with cancer are at highest risk of developing severe COVID-19 disease.
In this pandemic context, risks and benefits of receiving cancer treatment should be carefully weighted. Treatment RT delays and interruptions can negatively impact outcome and long-term survival. Another fact to consider is that in a ROD protective measures among staff and changes in its r egular workflow must be implemented when treating COVID-19 patients.
The objectives of this study are to analyze the incidence of COVID-19 in patients referred to RODs in Spain, subsequent treatment modifications and to determine death-related risk factors due to COVID-19.